Tirzepatide – 5mg

Tirzepatide, the active ingredient in both Mounjaro and Zepbound, is a novel dual GIP and GLP-1 receptor agonist medication that stimulates both incretin hormones to regulate blood glucose and appetite control. Clinical trials have shown it to be more effective than earlier GLP-1 medications like semaglutide, with some patients experiencing significant weight reduction. The medication works by improving insulin secretion, slowing gastric emptying, and reducing appetite through its dual-hormone action. While Mounjaro is primarily marketed for diabetes management, Zepbound contains the same compound specifically dosed for weight loss. Administered as a once-weekly injection with a gradual dose titration, common side effects include nausea, diarrhea, vomiting, and constipation.